Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.05 Insider Own0.70% Shs Outstand144.52M Perf Week2.97%
Market Cap6.61B Forward P/E66.05 EPS next Y0.69 Insider Trans6.19% Shs Float143.60M Perf Month-9.56%
Income-6.70M PEG- EPS next Q0.14 Inst Own96.00% Short Float3.36% Perf Quarter-1.23%
Sales563.10M P/S11.73 EPS this Y-33.30% Inst Trans-0.06% Short Ratio6.08 Perf Half Y-9.49%
Book/sh9.34 P/B4.89 EPS next Y41.22% ROA-0.40% Target Price50.92 Perf Year56.70%
Cash/sh3.82 P/C11.96 EPS next 5Y13.10% ROE-0.60% 52W Range28.86 - 54.25 Perf YTD12.42%
Dividend- P/FCF- EPS past 5Y-38.50% ROI1.90% 52W High-15.74% Beta1.08
Dividend %- Quick Ratio7.80 Sales past 5Y5.80% Gross Margin69.30% 52W Low58.39% ATR1.52
Employees1250 Current Ratio8.40 Sales Q/Q-20.30% Oper. Margin-0.10% RSI (14)41.66 Volatility2.97% 3.09%
OptionableYes Debt/Eq0.27 EPS Q/Q-950.00% Profit Margin-1.20% Rel Volume0.80 Prev Close46.21
ShortableYes LT Debt/Eq0.27 EarningsJul 24 Payout- Avg Volume792.23K Price45.71
Recom2.40 SMA20-5.42% SMA50-3.48% SMA2003.81% Volume630,191 Change-1.08%
10-Apr-14Upgrade Mizuho Neutral → Buy $55 → $61
09-Apr-14Reiterated MKM Partners Sell $32 → $35
28-Feb-14Reiterated UBS Neutral $42 → $53
28-Feb-14Reiterated MKM Partners Sell $26 → $32
28-Feb-14Reiterated Mizuho Neutral $33 → $56
05-Dec-13Downgrade UBS Buy → Neutral $37 → $42
01-Nov-13Reiterated Mizuho Neutral $30 → $33
30-Oct-13Initiated FBR Capital Mkt Perform $31
24-May-13Reiterated UBS Buy $32 → $37
24-May-13Downgrade MKM Partners Neutral → Sell
18-Apr-13Downgrade Mizuho Buy → Neutral $30 → $26
17-Apr-13Reiterated MKM Partners Neutral $23 → $25
23-Jan-13Downgrade MKM Partners Buy → Neutral
16-Nov-12Initiated Mizuho Buy $27
25-Jan-12Upgrade MKM Partners Neutral → Buy $19 → $20
23-Aug-11Upgrade UBS Neutral → Buy $20.50 → $21
08-Jul-11Reiterated UBS Neutral $19 → $20.50
07-Jun-11Reiterated UBS Neutral $16.50 → $19
10-May-11Reiterated UBS Neutral $14.50 → $16.50
20-Oct-10Downgrade Caris & Company Above Average → Average $16 → $10
24-Jul-14 04:00PM  Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Business Wire
23-Jul-14 07:10AM  Is Alkermes plc Stock Undervalued? at Motley Fool
21-Jul-14 03:40PM  Alkermes' Pipeline Development Impresses, Key Updates Ahead Zacks
17-Jul-14 07:05AM  Alkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS at theflyonthewall.com
07:00AM  Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis Business Wire
09-Jul-14 07:00AM  Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates Business Wire
08-Jul-14 12:47PM  Momentum names slammed as volatility comes back at CNBC
09:55AM  Why Mylan Should Buy Alkermes at Motley Fool
23-Jun-14 07:04AM  Alkermes plc (ALKS) Jumps: Stock Rises 5.7% Zacks
07:04AM  Alkermes plc (ALKS) Jumps: Stock Rises 5.7%
20-Jun-14 07:00AM  Lundbeck Delivers Some Data-Driven Upside at Seeking Alpha +5.71%
19-Jun-14 10:40AM  Alkermes' Aripiprazole Lauroxil Looks Promising Zacks
10:40AM  Alkermes' Aripiprazole Lauroxil Looks Promising
18-Jun-14 08:17AM  New Alkermes Schizophrenia Drug -- An Important Advance With Social Benefits at Forbes
08:17AM  New Alkermes Schizophrenia Drug -- An Important Advance With Social Benefits
07:03AM  Alkermes presents aripiprazole lauroxil phase 3 data theflyonthewall.com
07:03AM  Alkermes presents aripiprazole lauroxil phase 3 data
07:00AM  Alkermes Presents Phase 3 Data From Successful Pivotal Study of Aripiprazole Lauroxil for Treatment of Schizophrenia at ASCP Annual Meeting Business Wire
07:00AM  Alkermes Presents Phase 3 Data From Successful Pivotal Study of Aripiprazole Lauroxil for Treatment of Schizophrenia at ASCP Annual Meeting
11-Jun-14 04:00PM  Alkermes Progresses with its Late Stage Candidate Zacks
04:00PM  Alkermes Progresses with its Late Stage Candidate
10-Jun-14 07:05AM  Alkermes announces initiation of FORWARD-3, FORWARD-4 efficacy studies at theflyonthewall.com
07:05AM  Alkermes announces initiation of FORWARD-3, FORWARD-4 efficacy studies
07:00AM  Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461 for Treatment of Major Depressive Disorder Business Wire
07:00AM  Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461 for Treatment of Major Depressive Disorder
09-Jun-14 02:27PM  What's in a Name? Alkermes Thinks Alkeus is too Close for Comfort at The Wall Street Journal
02:27PM  What's in a Name? Alkermes Thinks Alkeus is too Close for Comfort
06-Jun-14 03:30PM  Alkermes' Pipeline Holds Promise Zacks
03:30PM  Alkermes' Pipeline Holds Promise
05-Jun-14 12:00AM  Sanofi, Alkermes Name, Pandora: Intellectual Property at Bloomberg
12:00AM  Sanofi, Alkermes Name, Pandora: Intellectual Property
03-Jun-14 07:00AM  Alkermes to Present Data on New Medicines in Development for Schizophrenia and Depression at Upcoming American Society of Clinical Psychopharmacology Annual Meeting Business Wire
02-Jun-14 07:00AM  Alkermes Announces Initiation of Second Phase 2 Clinical Study of ALKS 3831, a Novel Broad-Spectrum Oral Antipsychotic Business Wire
31-May-14 12:47AM  [$$] Ivy Mid Cap Growth: Rethinking Risk at Barrons.com
28-May-14 04:53PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur EDGAR Online
27-May-14 04:00PM  Alkermes Corporate Presentation to be Webcast at Two Upcoming Conferences Business Wire
16-May-14 08:50AM  Top Analyst Upgrades and Downgrades: J.C. Penney, Micron, Twitter, NBG, SanDisk and More at 24/7 Wall St.
05:38AM  Alkermes assumed with a Buy at Jefferies at theflyonthewall.com
14-May-14 07:16AM  Leerink to hold a bus tour at theflyonthewall.com
12-May-14 04:00PM  Alkermes Corporate Presentation to be Webcast at the UBS Global Healthcare Conference Business Wire
01-May-14 10:50AM  Wider-than-expected Loss at Alkermes, Revenues Slip Zacks
30-Apr-14 03:08PM  Alkermes' CEO Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
08:30AM  Alkermes plc Earnings Call scheduled for 8:30 am ET today CCBN
08:25AM  Alkermes plc Discusses Q4 2014 Results (Webcast) at Seeking Alpha
07:34AM  Alkermes plc Earnings Call scheduled for 8:30 am ET today CCBN
07:13AM  Alkermes says 'on track" to submit aripiprazole lauroxil NDA in Q3 theflyonthewall.com
07:07AM  Q1 2014 Alkermes plc Earnings Release - Before Market Open CCBN
07:06AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:00AM  Alkermes plc Reports First Quarter 2014 Financial Results Business Wire
23-Apr-14 04:00PM  Alkermes to Host Conference Call to Discuss First Quarter 2014 Financial Results Business Wire
17-Apr-14 08:31PM  Xenoport's Path Is Long, But The Potential Is There at Seeking Alpha
16-Apr-14 06:30PM  The Biggest Biotech Wins of the Week at Motley Fool +5.14%
09:07AM  Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data Zacks
11-Apr-14 06:41AM  Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% Zacks
10-Apr-14 03:39PM  Gilead Announces Encouraging Sovaldi Data Zacks
08:21AM  [video] Alkermes is a true drug innovator: CEO at CNBC
05:57AM  Alkermes upgraded by Mizuho Briefing.com
09-Apr-14 06:45PM  Lightning Round: Citigroup, Disney & More at CNBC +7.53%
05:30PM  Oncolytics Reports Additional Data on Reolysin Zacks
11:48AM  Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns Zacks
10:50AM  Positive Trial Data Lifts Alkermes Zacks
08-Apr-14 03:33PM  Alkermes to seek schizophrenia drug approval after trial success Reuters
03:21PM  Alkermes to seek schizophrenia drug approval after trial success Reuters
01:06PM  Why Alkermes PLC Shares Temporarily Spiked Higher at Motley Fool
12:57PM  Alkermes Scores Phase 3 Win for Long-Lasting Schizophrenia Drug at Motley Fool
12:12PM  Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3 at Investor's Business Daily
11:57AM  Alkermes to seek schizophrenia drug approval after trial success Reuters
11:51AM  [$$] Alkermes Treatment for Schizophrenia Shows Positive Results at The Wall Street Journal
11:10AM  Halozyme Falls on Phase II Study Halt Zacks
10:53AM  UPDATE 1-Alkermes' schizophrenia drug meets main goal of late-stage study Reuters
10:40AM  Bristol-Myers Seeks FDA Approval for HCV Candidates Zacks
09:26AM  RadNet Touches New 52-Week High Zacks
09:24AM  Ahead of the Bell: Alkermes shares jump AP
09:11AM  Alkermes Will Seek U.S. Approval for Once-Monthly Schizophrenia Treatment at TheStreet
08:00AM  The Boston Beer Company Earnings Call scheduled for 8:00 am ET today CCBN
08:00AM  Novartis AG Earnings Call scheduled for 8:00 am ET today CCBN
08:00AM  Alkermes Conference Call to discuss Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil scheduled for 8:00 am ET today CCBN
07:10AM  Alkermes' schizophrenia drug meets main goal of late-stage study Reuters
07:05AM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:04AM  Alkermes announces phase 3 'positive' results from aripiprazole lauroxil study at theflyonthewall.com
07:00AM  Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil for Treatment of Schizophrenia Business Wire
06:54AM  Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% Zacks
06:36AM  Agios Pharmaceuticals (AGIO) Surges: Stock Moves 27.8% Higher Zacks
07-Apr-14 06:30PM  Balanced Risk-Reward for EMCOR Group Zacks
06:00PM  Halozyme Falls on Phase II Study Halt Zacks
05:25PM  Expense Woes Persist at ProAssurance Zacks
04-Apr-14 07:05AM  Weakness Seen in Kindred Biosciences (KIN): Stock Tumbles 9.0% Zacks -6.53%
03-Apr-14 05:20PM  Good News for Keryx Zacks -5.06%
05:15PM  Glaxo Stops MAGE-A3 Lung Cancer Study Zacks
03:55PM  Encouraging Results on Gilead's Sovaldi Zacks
07:21AM  What Falling Estimates & Price Mean for bluebird bio (BLUE) Zacks
06:45AM  Should You Get Rid of Synageva BioPharma (GEVA) Now? Zacks
02-Apr-14 08:02PM  Why Tesla Motors, Acceleron Pharma, and Ballard Power Systems Jumped Today at Motley Fool
04:55PM  Eli Lilly Signs Deal with Prasco Zacks
03:30PM  FDA Panel Positive on MannKind's Afrezza Zacks
02:06AM  TetraLogic Pharmaceuticals (TLOG) Soars: Stock Up 20.7% Zacks
02:01AM  Palatin Technologies Inc. (PTN) Jumps: Stock Up 8.1% Zacks
01-Apr-14 03:45PM  Bayer's Adempas Cleared in the EU Zacks
02:15PM  Oxygen Biotherapeutics Up on FDA News Zacks
07:17AM  Alkermes recommended ahead of Phase 3 data at JPMorgan theflyonthewall.com
Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension and/or angina; and ZOHYDRO ER for severe pain. In addition, it is developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 33, which has completed Phase II study for modulation of brain opioid receptors; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a phase II study medicine to treat schizophrenia; ALKS 8700, a prodrug of monomethyl fumarate to treat multiple sclerosis; ALKS 7106, a small-molecule product candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary biologic cancer immunotherapy candidate. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. The company was founded in 1987 and is headquartered in Dublin, Ireland.